XML 26 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholders’ Deficiency (Tables)
6 Months Ended
Jun. 30, 2021
Stockholders' Equity Note [Abstract]  
Schedule of ordinary share capital
   June 30, 2021   December 31, 2020 
   Authorized   Issued and
outstanding
   Authorized   Issued and
outstanding
 
   Unaudited     
   Number of shares 
Ordinary Shares with no par value   47,800,000    18,756,570    47,800,000    18,494,739 

 

Schedule of status of the company’s option plan
   Number
of options
   Weighted
average
exercise
price
   Aggregate
intrinsic
value
 
   Unaudited 
             
Outstanding at beginning of period   2,193,392    5.72   $9,263 
Granted   56,000    10.07    58 
Exercised   (43,866)   6.42    227 
Forfeited and cancelled   (7,573)   6.62    19 
                
Outstanding at end of period   2,197,953    5.82    7,387 
                
Exercisable options   1,473,947    5.01    5,997 
                
Vested and expected to vest   2,197,953    5.82    7,387 

 

Schedule of the total equity-based compensation expense related to all of the company’s equity-based awards recognized
   Six months ended
June 30,
 
   2021   2020 
   Unaudited 
         
Research and development  $1,013   $762 
Market and business development   162    58 
General and administrative   1,063    1,437 
           
Total share-based compensation expense  $2,238   $2,257 

 

Schedule of options outstanding
Exercise
price
  Options
outstanding
as of
June 30,
2021
   Weighted
average
exercise
price
   Weighted
average
remaining
contractual
term
   Options
exercisable
as of
June 30,
2021
   Weighted
average
exercise
price
   Weighted
average
remaining
contractual
term
 
           (years)           (years) 
                         
*)0.22   
245,535
    *)0.22   1.72    
245,535
    *)0.22   1.72 
1.75   107,904    1.75    1.72    107,904    1.75    1.72 
3.59   83,503    3.59    2.26    83,503    3.59    2.26 
5.07   253,722    5.07    3.00    253,722    5.07    3.00 
9.23   199,930    9.23    4.07    199,930    9.23    4.07 
3.10   26,959    3.10    4.94    26,959    3.10    4.94 
3.93   51,385    3.93    5.48    51,385    3.93    5.48 
4.10   20,914    4.10    5.69    20,914    4.10    5.69 
4.18   1,195    4.18    5.90    1,195    4.18    5.90 
7.70   59,345    7.70    6.34    59,345    7.70    6.34 
8.42   7,589    8.42    7.28    6,625    8.42    7.28 
8.65   14,340    8.65    7.11    12,840    8.65    7.11 
8.02   26,290    8.02    7.73    19,611    8.02    7.73 
6.80   58,731    6.80    8.62    25,222    6.80    8.62 
6.62   894,511    6.62    8.96    359,257    6.62    8.96 
11.04   90,100    11.04    9.37    
-
    11.04    
-
 
10.07   56,000    10.07    9.62    
-
    10.07    
-
 
                               
    2,197,953    5.82    6.16    1,473,947    5.01    4.76 

 

*)The exercise price as per the option terms was denominated in NIS and translated to $ in the table above using the exchange rate as of the grant date. The options were granted at Ordinary Share par value.

  

Schedule of outstanding options granted to consultants
Grant date  Options
outstanding
as of
June 30,
2021
   Exercise
price
per share
   Options
exercisable
as of
June 30,
2021
   Exercisable
through
                
October 2013   5,719   $5.07    5,719   October 2023
September 2014   5,719   $5.07    5,719   September 2024
April 2016   5,975   $3.10    5,975   April 2026
December 2016   7,170   $3.93    7,170   December 2026
June 2017   197,722   $4.10    156,970   June 2027
November 2017   17,925   $7.70    17,925   November 2027
August 2019   71,700   $8.18    67,197   August 2029
June 2020   64,530   $6.62-$6.80    21,306   June 2030
April 2021   62,741   $9.57    
-
   April 2031
                   
    439,201         287,981